<DOC>
	<DOCNO>NCT00941603</DOCNO>
	<brief_summary>The purpose study evaluate effect SCH 900271 compare placebo reduction low-density lipoprotein cholesterol ( LDL-C ) baseline 8 week treatment participant primary hypercholesterolemia ( familial nonfamilial ) mix hyperlipidemia . The study also evaluate effect SCH 900271 non-high density lipoprotein cholesterol ( non-HDL-C ) various lipid lipoprotein . The safety SCH 900271 participant population also evaluate .</brief_summary>
	<brief_title>Phase 2 Dose-Ranging Efficacy Safety Trial SCH 900271 Participants With Primary Hypercholesterolemia Mixed Hyperlipidemia ( P05675 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipidemia , Familial Combined</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type V</mesh_term>
	<mesh_term>Lipidoses</mesh_term>
	<criteria>Adults either sex 18 75 year age , inclusive , diagnosis primary hypercholesterolemia ( familial nonfamilial ) mixed hyperlipidemia ( increase LDLC triglyceride [ TG ] ) must free clinically significant disease , primary hypercholesterolemia mixed hyperlipidemia would knowingly interfere study evaluation must willing adhere dietary recommendation , protocol requirement , provide write informed consent The participant exclude entry ANY criterion list met : use investigational drug within 30 day study entry female childbearing potential lactating postmenopausal ( perimenopausal ) woman currently experience hot flash ( e.g . within 30 day study entry homozygous familial hypercholesterolemia congestive heart failure New York Heart Association ( NYHA ) Class III IV uncontrolled hypertension therapy cardiac arrhythmia require medication clinical atherosclerotic disease confers high risk coronary heart disease ( CHD ) event ( e.g . clinical CHD , symptomatic carotid artery disease , peripheral arterial disease , abdominal aortic aneurysm ) Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus history mental instability , drug/alcohol abuse treat treat severe psychiatric illness , opinion investigator , may interfere optimal participation study gastrointestinal ulcer within 3 month study entry history coagulopathy history gout know active chronic hepatic biliary disease . know significant impairment renal function , dysproteinemia , nephrotic syndrome , renal disease body mass index &gt; 40 kg/m^2 take nonsteroidal antiinflammatory drug ( NSAIDS ) ( acetaminophen cyclooxygenase2 [ COX2 ] inhibitor allow ) take 100 mg aspirin per day treat corticosteroid ( oral , intramuscular , intravascular ) 3 alcoholic beverage per day equivalent ( one drink equal 1.5 ounce 80 proof liquor equivalent ) study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>